For the purpose of cancer immunotherapy, monoclonal antibodies have been generated to potentiate the ongoing antitumor immune response of the patient, through “immune checkpoint blockade” of CTLA-4, PD-1, or PD-1 ligand (PD-L1). The gene discussed is CTLA4; the disease is cancer.